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Abstract  
Introduction: The change in bone turnover markers (BTM) in response to osteoporosis therapy can be 
assessed by a decrease beyond the least significant change (LSC) or below the mean of the reference 
interval (RI).  We compared the performance of these two approaches in women treated with raloxifene.  
Methods: Fifty postmenopausal osteopenic women, (age 51-72y) were randomised to raloxifene or no 
treatment for 2 years.  Blood samples were collected for the measurement of BTM.  The LSC for each 
marker was calculated from the untreated women and the RI obtained from healthy premenopausal women 
(age 35-40y). Bone mineral density (BMD) was measured at the spine and hip.     
Results:  There was a decrease in BTM in response to raloxifene treatment; percentage change at 12 weeks, 
CTX -39% (95% CI -48 to -28) and PINP -32% (95% CI -40 to -23) P<0.001.  The proportion of women 
classified as responding to treatment using LSC at 12 weeks was: CTX 38%, PINP 52%, at 48 weeks CTX 
60%, PINP 65%.  For the RI approach; at 12 weeks CTX and PINP 38%, at 48 weeks CTX 40%, PINP 
45%.   There was a significant difference in the change in spine BMD in the raloxifene treated group 
compared to the no-treatment group at week 48; difference 0.031 g/cm2, (95% CI 0.016 to 0.046, P<0.001).  
Conclusions:  The two approaches identified women that reached the target for treatment using BTM.    
Both LSC and RI criteria appear useful in identifying treatment response but the two approaches do not 
fully overlap and may be complementary.     
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Mini abstract:  
We used two methods of identifying women who reached the target for raloxifene treatment with bone 
turnover markers.  Both approaches identified women that responded to treatment, but did not fully 
agree and may be complementary.   
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Background 
Raloxifene is a selective estrogen receptor modulator (SERM) that has beneficial effects on bone and lipids 
with no detrimental effects on the breast or endometrium [1, 2]  and is licensed for the treatment and 
prevention of osteoporosis [3] .  Raloxifene treatment results in an increase in bone mineral density (BMD), 
reduction in bone turnover markers (BTM) and reduced risk of vertebral fractures [4-6] .  A systematic 
analysis of clinical trials demonstrated that raloxifene reduces the risk of vertebral fracture by 40 to 49% in 
postmenopausal women with osteoporosis [7] .  The magnitude of change in BTM and BMD with 
raloxifene treatment is of a smaller magnitude compared to other, more potent treatments for osteoporosis 
such as bisphosphonates. 
 
Bone turnover markers are established as useful tools in research studies of metabolic bone disease as they 
show a biological response to the treatment of osteoporosis [8, 9] .  In clinical trials, the changes in bone 
turnover markers have been shown to be related to change in fracture risk [10] .  There is evidence that 
there is an association between the change in bone formation markers but not bone resorption markers on 
raloxifene and the reduction in spine fracture risk [5, 11-13] .   Changes in bone markers in response to 
treatment occur earlier and are of a greater magnitude than changes in bone density.  A significant change 
in BMD can rarely be detected in an individual in response to oral anti-resorptive therapy in less than 18-24 
months.  Compliance with treatment is a concern in clinical practice and monitoring patients on treatment 
using biochemical markers can provide useful additional information for the management of patient care 
[14] .   
 
There are limited data on the use of bone markers in clinical practice.  In a retrospective study of the utility 
of urinary N telopeptide of type I collagen (NTX) to monitor bisphosphonate treatment, a poor response 
defined by change in NTX, was associated with early identification of non-compliance or the presence of 
secondary osteoporosis [15] .  This suggests that bone turnover markers are useful tools in clinical practice 
for the management of patients with osteoporosis.   However, the use of bone markers for patient 
management is not common practice.  Considerations for their use in clinical practice include cost 
effectiveness and also the variability of bone markers [16, 17] .  Studies have reported poor reproducibility 
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of bone markers between laboratories [18, 19] . The standardization of bone marker measurements is 
currently being addressed with the introduction of international reference standards [10] .  It has been 
proposed that the C terminal telopeptide of type I collagen (CTX) and N terminal propeptide of type I 
procollagen (PINP) are adopted as reference bone markers.   
 
There are two methods that have been proposed when using bone markers to assess response to 
osteoporosis treatment [10] .  Firstly the least significant change (LSC) approach which is the minimum 
change in bone markers that can be attributed to the treatment effect rather than random variation in the 
marker, or secondly a reduction in bone markers to below the mean of the reference interval (RI) for 
premenopausal women [10, 12] . Both of these approaches can be useful to monitor the response to 
bisphosphonate treatment using bone markers [20] , however the use of BTM for monitoring less potent 
treatment may not be as informative.  There are limitations to both described approaches; there is no 
consensus for the calculation of least significant change and the reference intervals should be appropriate 
and robust.   
 
The aim of this work was to identify the proportion of women that reach the goal for response to raloxifene 
treatment using the LSC and RI criteria and thereby assess their potential utility to monitor treatment 
response to this agent in clinical practice. 
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Materials and methods 
Subjects 
Postmenopausal women with osteopenia, ages 50 to 80 years were recruited from general practice surgeries 
or new patient referrals for BMD measurements. Women were eligible if they had osteopenia at either the 
lumbar spine or proximal femur (BMD T-score between -1and -2.5 SD) measured by dual energy x-ray 
absorptiometry (DXA). The participants completed an osteoporosis risk factor questionnaire at the 
screening visit with laboratory investigations to identify co-morbidities which could affect bone 
metabolism (screening investigations: FBC, ESR, TSH, bone profile, electrolytes, liver function tests, 
serum and urine electrophoresis, and 24-hour urine calcium excretion).    Exclusion criteria included the 
presence of metabolic bone disease or other medical condition that would affect bone metabolism; use of 
hormone replacement therapy or other antiresorptive treatments within the previous 6 months; history of 
hepatic or renal impairment, venous thromboembolic disease; unexplained uterine bleeding or malignancy. 
Women with degenerative disease of the spine or evidence of two or more vertebral fractures between L1 
and L4 on the DXA lumbar spine scan were also excluded.  Healthy premenopausal women ages 35 to 40 
years were recruited to establish a premenopausal reference interval.  This study population has been 
described elsewhere [20, 21] .  The women who were included had regular menstrual cycles and were 
vitamin D replete (25OHD >50nmol/L).  Exclusion criteria included the use of oral prednisolone (or 
equivalent) and bone active drugs, any disease that affects bone metabolism, presence of recent fracture 
(within 12 months), surgical operation (within 3 months), pregnancy or current use of contraceptive pill.   
The raloxifene study was approved by the Sheffield Research Ethics Committee and signed informed 
consent was obtained from each participant prior to inclusion into the study.  The use of samples was 
approved by the Sheffield Musculoskeletal Biobank, which received ethics approval from the NRES REC 
South Central Oxford C, (REC ref 10/H0606/20) and is housed in the University of Sheffield Biorepository 
(HTA Licence no. 12182). 
 
Study intervention 
In this controlled open label study, 50 postmenopausal osteopenic women were randomised to receive 
raloxifene (60 mg/day Evista, Eli Lilly and Co., Indianapolis, IN) plus elemental calcium 500mg/day as 
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calcium carbonate (Calcichew: Shire Pharmaceuticals Ltd., Andover, Hants, UK) or to receive no 
treatment.  Adherence was assessed using medical events monitoring system (MEMS) bottle caps 
(AARDEX, Zurich, Switzerland), which record the date and number of times a medication bottle is opened 
[22] . Complete MEMS data were available for 17 of the 21 women, 12 women had compliance >80% and 
5 women >60%.  The study was conducted in accordance with ethical recommendations for monitoring 
adherence [23] . The 87 healthy premenopausal women were not prescribed any medication during the 
study [20] .  
 
Study assessments 
Anthropometric measurements included height (to nearest 0.1cm), weight (to nearest 0.1kg) (Seca 
Birmingham UK).  Bone mineral density (BMD, g/cm2) of the lumbar spine (LS), femoral neck (FN) and 
total hip (TH) were measured by dual energy x-ray absorptiometry (DXA) using Hologic QDR1000W, 
(Hologic Inc, Bedford MA, USA). The mean BMD was calculated from two DXA scans performed a week 
apart at baseline and again at 48 and 96 weeks. The coefficients of variation were calculated from baseline 
duplicate measurements the CVs were 1.5% (LS), 2.7% (FN), 1.9% (TH)  [24]   
 
Biochemistry 
Samples for biochemistry were collected from the postmenopausal women who attended for regular visits 
over 2 years.  Blood was collected after an overnight fast and serum stored at -80°C until analysis in one 
analytical batch.  Fasting blood samples were collected at baseline from the healthy premenopausal women.  
The C-terminal telopeptide of type I collagen (CTX), intact pro-collagen I N-propeptide (PINP), 25 
hydroxyvitamin D (25OHD) and parathyroid hormone (PTH) were measured in serum by IDS-iSYS 
automated immunoassays (Immunodiagnostic Systems, Boldon, UK) inter-assay CV 6.5%, 7.2%, 6.7% and 
6.5% respectively.  
 
 
Statistical analysis 
 
For analysis of change in bone turnover markers from baseline, a treatment group comparison was made 
using a mixed effects repeated measures model with baseline measurement fitted as a covariate.  If an 
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overall statistically significant difference was found between treatment and no treatment groups then the 
effect of treatment was assessed at each time point.  A within-treatment group analysis was performed to 
determine if the change in bone turnover marker was significant over time.  If an overall statistically 
significant difference was found over time then the change from baseline was assessed at each time point.  
All bone turnover marker measurements were log10 transformed prior to analysis and changes from baseline 
were back transformed and expressed as a percentage change.  Missing values were imputed using last 
observation carried forward. 
The differences in the change from baseline in BMD between the treatment and no treatment group were 
assessed at 48 and 96 weeks using analysis of covariance (ANCOVA) with baseline measurement fitted as 
a covariate. 
 
Least significant change (LSC) for the bone turnover markers was calculated using measurements from the 
no treatment group over 12 weeks.  This is the minimum difference between two measurements that can be 
considered a true change due to treatment rather than random variability in the measurement.  The 
distribution of the measurements was positive skewed so a log10 transform was used to give an approximate 
Normal distribution.  LSC was then calculated on the log-transformed data as follows: ܮܵܥ௟௢௚ ൌ ܼᇱ  ൈ   ? ? ൈ ܵܦோெௌ 
 
where SDRMS is the root-mean-square standard deviation calculated from the log-transformed data, and Z' is 
equal to 1.96 for 95% confidence level.   
The LSC as a percentage change on the original scale is then given by: ܮܵܥ ൌ  ? ? ? ൈ ൫ ? ?േ௅ௌ஼೗೚೒ െ  ?൯ 
 
The goal for LSC response was defined as a percentage decrease from baseline in bone marker greater than 
the lower limit of the LSC.  This was calculated at 12 and 48 weeks of treatment.    
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The reference interval was calculated from premenopausal women who were vitamin D replete (25OHD 
>50 nmol/L) using log transformed data  [20] .    The goal for RI response was defined as a bone marker 
result below the mean for the premenopausal reference interval, calculated at 12 and 48 weeks of treatment.     
 
The longitudinal mixed effects repeated measures models were fitted using IBM SPSS Statistics for 
windows Version 21.0 (Armonk, NY) and plots were created in R (http://cran.r-project.org/). 
 
Bone mineral density 
Change from baseline in DXA BMD was calculated for LS, FN and TH.  The treatment group was 
compared to the no-treatment group at 48 and 96 weeks using analysis of covariance adjusting for baseline 
measurement.  
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Results 
 
The baseline characteristics of the study participants are shown in Table 1.  Spine BMD was lower and 
BTM higher in the postmenopausal osteopenic women compared to the healthy premenopausal controls. 
There were 6 participants that withdrew from the study before 48 weeks and so were not included in the 
analysis, (5 in the treatment group and 1 in the no treatment group).   One participant in the treatment group 
had no sample for the week 48 visit.  Data for the BTMs are shown up to 48 weeks as after this time-point 
there was no further decrease in response to treatment.   
 
Percentage change from baseline 
The time course and magnitude of response of BTM to raloxifene treatment are shown in Figure 1.  There 
was an overall statistically significant difference between the no treatment and treatment groups for BTM 
P< 0.001.  The within week analysis shows that the between group differences are statistically significant at 
every time point for the BTM; CTX and PINP (P<0.001).  There is an overall difference from baseline over 
time in the treatment group CTX, PINP (P<0.001).  The mean percentage change in BTM from baseline are 
shown in Table 2.   The decrease in CTX was early and below baseline by week 1 (-21%, 95% CI -27 to -
14, P<0.001), the decrease from baseline was significant at week 4 for PINP (-17% 95% CI -28 to -4, 
P=0.014).    
 
Response to treatment  
The target for response to treatment was defined as a percentage change in BTM greater than the LSC or as 
a result that was in the lower half of the premenopausal reference interval.  The percentage change from 
baseline at 12 weeks for individual participants with the LSC for PINP and CTX are shown in Figure 2.  
Four women had an increase in BTM at this time point.  The two women had an increase in PINP from 
baseline at 12 weeks, this had decreased by 48 weeks.  Both had a high CTX at baseline and had good 
compliance as assessed by MEMS data (89% and 97%).  One of the women had a high baseline PTH and 
low 25OHD.  Two women had an increase in CTX at 12 weeks, one had low baseline CTX which may 
have influenced the large percentage change result and her PINP was decreased at 12 weeks (-37%).   The 
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second woman had poor compliance throughout the study (65%) and only a small percentage change in 
PINP at 12 weeks (-5%).        
 
The number of women classified as responders by the two criteria at 12 weeks and at 48 weeks are shown 
in Table 3.   Using the LSC criteria more women reached the target for response at 12 weeks for PINP 
(52%), than for CTX (38%).  By 48 weeks the number of women reaching the goal for treatment was 65% 
for PINP and 60% for CTX.   
 
The absolute values for CTX and PINP are shown in Figure 3.  At baseline 14% of women were below the 
mean of the reference interval for CTX and 10% for PINP (Table 3).  At 12 weeks 8/21 (38%) were below 
the RI mean for CTX and PINP (Table 3).  Of the 8 women below the RI mean for CTX at 12 weeks, 3 did 
not remain below at 48 weeks.  However another 3 women were below the mean at 48 weeks only, so the 
total remained at 8 women.  The 8 women below the RI for PINP at 12 weeks, remained the same at 48 
weeks with one additional person reaching the premenopausal mean.  The model used to calculate the mean 
change from baseline accounted for the baseline BTM values.  The baseline BTM value did not influence 
the magnitude of change in BTM.   
 
At the 12 week visit for PINP 6 of the 21 women were classified as responding to treatment by both LSC 
and RI methods, 7 by either LSC or RI and 8 non-responders. For CTX 4 of the 21 women were classified 
by both LSC and RI 6 by one of the criteria and 11 non-responders.  Five women did not reach the target 
response for LSC or RI in either PINP or CTX. These included 3 of the 4 women who had an increase in 
BTM at 12 weeks compared to baseline.  A total of 15 women were classified as reaching the target for 
response by LSC method and 9 for the RI criteria, by either CTX or PINP or both.       
 
Bone Density  
There was a significant difference in the absolute change in lumbar spine BMD in the raloxifene treated 
group mean 0.017 g/cm2 (SD 0.019) compared to the no-treatment group -0.010 g/cm2 (SD 0.027) at week 
48; difference (adjusted for baseline) 0.031 g/cm2, 95% CI 0.016 to 0.046, P<0.001.  At 96 weeks the 
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difference was mean 0.029 g/cm2 (95% CI 0.004 to 0.053) P=0.024.  There was no difference between the 
treatment and no treatment groups in the change in BMD at total hip or femoral neck.  Total hip week 96 
difference 0.013 g/cm2 (95% CI -0.008 to 0.035, P=0.219), FN difference 0.014 g/cm2 (95% CI -0.014 to 
0.042, P=0.306).  At 96 weeks 3 women had a change in LS BMD greater than the LSC (-3.6%) and 1 for 
hip BMD (LSC TH -4.2%, FN -6.1%).         
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Discussion 
There was a decrease in BTM in response to raloxifene treatment, at 12 weeks there was a 39% decrease in 
CTX, and 32% decrease in PINP.  Other studies have reported a similar decrease in BTM in response to 
raloxifene for CTX measured using other methods [1, 2, 25]  and for total PINP measured by a different 
autoanalyser method [26] .  The changes in BTM occur earlier and are of a greater magnitude than the 
change in bone density.  
 
The two approaches that have been proposed as ways to assess response to treatment using BTM are a 
change greater than the LSC or a reduction to below the mean of the premenopausal RI.  
We found that both approaches identified women that responded to raloxifene treatment.  Bone density 
measurements after 2 years were only greater than the LSC for spine BMD for 3 women.  There were 5 
women who did not reach the target for treatment by either method for bone markers.  Two of the women 
had poor compliance and others had possible confounding factors including high PTH and low 25OHD, 
thyroidectomy and steroid use.   
 
One of the limitations of the RI approach is the overlap of results for pre and postmenopausal women [8] .   
For women who are below the mean of the reference interval at baseline, the clinician would look for a 
change in response to raloxifene from the pre-treatment value within the reference interval.   
 
The proportion of women classified as responders by the LSC method was fewer than reported for other 
treatments.  This is not unexpected as the percentage change in BTM in response to raloxifene is less than 
that for other osteoporosis treatments such as bisphosphonates [4, 20, 27, 28] .  For example we have 
reported previously in a study of postmenopausal women treated with bisphosphonates (TRIO study) that 
12 weeks of alendronate therapy resulted in 98% responders by CTX and 82% by PINP for LSC; that 
contrasts with the response to raloxifene therapy at 12 weeks which was 38% for CTX and 52% for PINP 
(Table 3)  [20] .  The LSC was less for the raloxifene study -45% CTX and -27% PINP in comparison to 
the TRIO study (-56% CTX, -38% PINP).   There are several ways that LSC can be calculated [10, 29] . 
Factors to consider include one-tailed or two tailed, level of significance, the population that it is calculated 
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from and over what time course.  For monitoring treatment in clinical practice it has been suggested that a 
one-sided probability of 0.05 is appropriate as a decrease in BTM is expected.  It has also been suggested 
that a probability of 80% is adequate for monitoring treatment.  It would be useful to have a consensus on 
the LSC calculation.   
 
The LSC threshold and the RI mean should be considered as a guideline to help with clinical decisions. The 
LSC represents a statistical approach and not a true biological change in response to treatment.   Women 
who have had a decrease in BTM that has not exceeded the LSC have not reached the goal for response 
may have still had a change in bone markers in response to the treatment.  For those women in the lower 
half of the reference interval at baseline it is clinically relevant to monitor their change within the RI during 
treatment.  Many factors are considered when making clinical judgements and the change in BTM offers 
additional information that could help with decisions for patient management.   
 
A response to treatment is dependent on patient compliance.  However, treatment response may be 
suboptimal even in patients who take their treatment and may reflect intermittent compliance or poor 
absorption. Measuring the BTM response is useful in addition to talking to the patient to identify that 
although they are taking the treatment the desired response is not achieved, this would be identified earlier 
than measuring the BMD response.  Earlier identification of poor response enables treatment to be 
reviewed, investigation for cause of poor response to be undertaken and changes in management to be 
instituted in a timely way.       
 
When monitoring change in bone markers the regression to the mean should be considered. [30, 31] . 
Regression to the mean is a statistical phenomenon that can make natural variation in repeated data look 
like real change. It happens when unusually large or small measurements tend to be followed by 
measurements that are closer to the mean [32] . Regression to the mean should not be an issue in the change 
from baseline analysis because this is a randomised study (if subjects are randomly allocated to comparison 
groups then all groups should be equally affected by regression to the mean) and the baseline measurement 
was adjusted for in the mixed effects model that we used. 
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The limitations of this study are the small number of participants.  We did not have sufficient numbers to 
assess whether the change in BMD was different for those that reached the target response compared to 
those that did not, or whether the change in bone markers was greater for those with the highest baseline 
results or better compliance.  The long term storage of the samples may influence the BTM measurements, 
there are no published data on the effect of long term storage on the assays used.   
 
In conclusion bone markers offer a way to monitor response to osteoporosis treatment so that the 
management of the patient can be adjusted if necessary at an early stage in treatment.   
Both LSC and RI criteria appear useful in identifying treatment response but the two approaches do not 
fully overlap.  The response of BTM provides additional information that can complement other clinical 
information for patient management.  For markers to be useful in clinical practice, using either of these 
approaches for determining responders, there should be a consensus on LSC calculation and robust 
reference intervals established using data from large populations.    
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Table 1.  Baseline characteristics for postmenopausal women randomised to raloxifene or no treatment and 
the premenopausal reference group.  Results are shown as mean (SD) for demographics and median (inter 
quartile range) for biochemistry results. 
 
 Raloxifene  No treatment Premenopausal  
n 21 23 87 
Age, years 63 (7) 61 (6) 38 (2) 
Height, cm 161 (6) 161 (6) 165 (7) 
Weight, kg 70 (12) 72 (16) 67 (11) 
LS BMD g/cm2 0.857 (0.060) 0.903 (0.098) 1.092 (0.117) 
25OHD ʅg/L 17 (13 to 32) 19 (12 to 32) 28 (23 to 31) 
PTH pg/mL 36 (25 to 45) 30 (25 to 40) 29 (23 to 37) 
CTX ʅg/L 0.68 (0.47 to 0.93) 0.55 (0.34 to 0.73) 0.32 (0.23 to 0.41) 
PINP ʅg/L 47 (37 to 59) 50 (27 to 60) 29 (22 to 35) 
 
Table 2: Percentage change from baseline for BTM in the treatment group over 48 weeks.  
 
 CTX PINP 
 % Change 95%CI P-value % Change (95% CI) P-value 
Week 1 -21 (-27, -14) <0.001 -10 (-18, -1) 0.036 
Week 2 -28 (-38, -16) <0.001 -6 (-15, 4) 0.230 
Week 4 -37 (-49, -23) <0.001 -17 (-28, -4) 0.014 
Week 8 -37 (-47, -25) <0.001 -22 (-31, -11) <0.001 
Week 12 -39 (-48, -28) <0.001 -32 (-40, -23) <0.001 
Week 24 -44 (-55, -31) <0.001 -40 (-47, -32) <0.001 
Week 36 -48 (-59, -34) <0.001 -42 (-49, -34) <0.001 
Week 48 -48 (-60, -33) <0.001 -39 (-49, -28) <0.001 
 
Table 3. Responder analysis for least significant change (LSC) and reference interval (RI)  
 
BTM visit n  
LSC 
LSC 
responders 
Geometric 
mean (RI) 
 RI 
responders 
CTX Baseline 21 -45%  - 0.32 µg/L 
(0.13 to 0.81) 
 3 (14%) 
12 Weeks 21 8 (38%) 8 (38%) 
48 Weeks 20 12 (60%) 8 (40%) 
PINP Baseline 21 -27% - 28 µg/L  
(15 to 54) 
2 (10%) 
12 Weeks 21 11 (52%) 8 (38%) 
48 Weeks 20 13 (65%) 9 (45%) 
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Figure 1.  The percentage change (mean and SEM) in CTX and PINP over 48 weeks.   The women treated 
with raloxifene are shown as the grey line with circles, the women receiving no-treatment as the black line 
with squares. 
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Figure 2. Percentage change from baseline for CTX and PINP at 12 weeks for the women treated with 
raloxifene; shaded area shows the LSC. The target for treatment is a decrease beyond the LSC.  
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Figure 3. Box and whisker plot of absolute values for CTX and PINP over 48 weeks for the women treated 
with raloxifene; the box represents the interquartile range, the middle solid line is the median and the 
whiskers show the range of the data.  The premenopausal reference interval is shown by the shaded area, 
the geometric mean shown by the black dashed line. The target for treatment is below the mean for the 
premenopausal reference interval.   
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